We love to hear from our listeners. Send us a message.

Vaxxinity’s John Krayacich likes taking big swings at big indications. He’s played key roles on the teams that launched Lipitor, Lyrica, and Neurontin, which have had measurable impacts on global populations of people suffering from cardiovascular disease, CNS disorders, and pain. He found those opportunities at companies like LEO, Novartis, Parke Davis, and Pfizer. Now, Krayacich is taking big swings at a new set of incredibly challenging candidates—immunotherapeutic vaccines for neurodegenerative and chronic diseases like Alzheimer’s, Dementia with Lewy Bodies, Multiple System Atrophy, Parkinson’s, Migraine, and Hypercholesterolemia. On this episode of the Business of Biotech, the Chief Business Officer shares his inspiration and strategy for seeing therapeutics for big, global patient populations through the commercial finish line. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/